SCHEMBL69454

SCHEMBL69454

COC(=O)c1ccc(Cc2ccc(C(=O)OC)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.70
CA1 P00915 4/20 0.65
CA2 P00918 4/20 0.65
CA12 O43570 2/20 0.65
CA9 Q16790 2/20 0.65
CA14 Q9ULX7 2/20 0.65
CYP4A11 Q02928 2/20 0.63
TDP1 Q9NUW8 1/20 0.61
CA7 P43166 1/20 0.61
CYP4F2 P78329 1/20 0.61
MAPT P10636 2/20 0.61
ALDH1A1 P00352 2/20 0.61
AR P10275 1/20 0.58
KMT2A Q03164 2/20 0.58
TSHR P16473 2/20 0.58
MEN1 O00255 1/20 0.57
KDM4E B2RXH2 1/20 0.54
NPC1 O15118 1/20 0.54
GAA P10253 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31147141 0.92 LOXL2 (0.61) LOXL2CA1CA2CA12CA9
SCHEMBL481297 0.92 LOXL2 (0.61) LOXL2CA1CA2CA12CA9
SCHEMBL12856272 0.92 KMT2A (0.73) LOXL2CA1CA2CA12CA9
SCHEMBL16155876 0.92 TDP1 (0.77) LOXL2CA1CA2CA12CA9
SCHEMBL6158387 0.92 TSHR (0.67) LOXL2CA1CA2CA12CA9
SCHEMBL6844835 0.90 LOXL2 (0.59) LOXL2CA1CA2CA12CA9
SCHEMBL7411710 0.90 NPC1 (0.60) LOXL2CA1CA2CA12CA9
SCHEMBL4245233 0.90 LOXL2 (0.65) LOXL2CA1CA2CA12CA9
SCHEMBL9234845 0.90 CA1 (0.60) LOXL2CA1CA2CA12CA9
SCHEMBL481090 0.90 LOXL2 (0.59) LOXL2CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014170799-A1 CROSSLINKABLE VARNISH AND METHOD FOR APPLYING SAME COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-10-23 WO claimed
CN-119242195-A Antifouling polyester film for solar cell front plate and preparation method thereof 江苏双星彩塑新材料股份有限公司 2025-01-03 CN disclosed
CN-118832938-A Antistatic solar cell front plate and preparation method thereof 江苏双星彩塑新材料股份有限公司 2024-10-25 CN disclosed
CN-118702903-A Modified polyester masterbatch for textile applications and method of making same 埃斯特尔工业有限公司 2024-09-27 CN disclosed
CN-221588401-U Antifog film for solar cell front plate 江苏双星彩塑新材料股份有限公司 2024-08-23 CN disclosed
CN-118496774-A Anti-fog film for front panel of solar cell and preparation method thereof 江苏双星彩塑新材料股份有限公司 2024-08-16 CN disclosed
CN-221496701-U Preparation system for flame-retardant master batch for solar cell backboard 江苏双星彩塑新材料股份有限公司 2024-08-09 CN disclosed
CN-118406352-A Flame-retardant master batch for solar cell backboard and preparation method thereof 江苏双星彩塑新材料股份有限公司 2024-07-30 CN disclosed
CN-221392400-U Manufacturing equipment for polyester film for MLCC high-smoothness release film 江苏双星彩塑新材料股份有限公司 2024-07-23 CN disclosed
CN-118359997-A Protective film and solar cell front plate 江苏双星彩塑新材料股份有限公司 2024-07-19 CN disclosed
US-20100183330-A1 IMAGE-FORMING APPARATUS AND CARTRIDGE MITSUBISHI CHEMICAL CORPORATION (JP) 2010-07-22 US disclosed
WO-2010075030-A1 POLYMERIZATION OF ALIPHATIC-AROMATIC COPOLYETHERESTERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-07-01 WO disclosed
WO-2010071771-A1 POLYMERIZATION WITH ENHANCED GLYCOL ETHER FORMATION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-06-24 WO disclosed
WO-2009155362-A1 SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2009-12-23 WO disclosed
US-20080146768-A1 PROCESSES FOR PREPARING POLYMERS USING ALPHA,OMEGA-DIFUNCTIONAL ALDARAMIDES E. I. DU PONT DE NEMOURS AND COMPANY 2008-06-19 US disclosed
EP-1858955-A1 PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2007-11-28 EP disclosed
US-20060264672-A1 Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers E. I. DU PONT DE NEMOURS AND COMPANY 2006-11-23 US disclosed
WO-2006091901-A1 PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-08-31 WO disclosed
US-4151213-A REACTION PRODUCT OF TRANSITION METAL HALIDE WITH SILVER NITRITE FOR OXIDIZING ALKYLAROMATICS STANDARD OIL COMPANY (INDIANA) (US) 1979-04-24 US disclosed
US-4042531-A TRANSITION METAL HALIDE AND SILVER NITRITE STANDARD OIL COMPANY (INDIANA) (US) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264672-A1 Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers ALOX5, GSTO1, FASN LOXL2 698/4885CA1 3029/4885CA2 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.